Nanovibronix (NASDAQ:FEED – Get Free Report) and Bioventus (NASDAQ:BVS – Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability and risk.
Profitability
This table compares Nanovibronix and Bioventus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nanovibronix | -275.12% | -24.78% | -19.24% |
| Bioventus | 1.39% | 26.38% | 7.27% |
Institutional and Insider Ownership
16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 1.4% of Nanovibronix shares are owned by company insiders. Comparatively, 33.0% of Bioventus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Risk and Volatility
Analyst Ratings
This is a breakdown of recent ratings and price targets for Nanovibronix and Bioventus, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
| Bioventus | 0 | 1 | 0 | 1 | 3.00 |
Earnings & Valuation
This table compares Nanovibronix and Bioventus”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nanovibronix | $2.56 million | 1.20 | -$3.70 million | ($41.74) | -0.07 |
| Bioventus | $573.28 million | 1.19 | -$33.54 million | $0.12 | 68.92 |
Nanovibronix has higher earnings, but lower revenue than Bioventus. Nanovibronix is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.
Summary
Bioventus beats Nanovibronix on 10 of the 13 factors compared between the two stocks.
About Nanovibronix
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
About Bioventus
Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company’s restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician’s office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.
